The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries

Journal of Hypertension

Volumn 30, Issue 5, 2012, Pages 980-989

  Grisk, Olaf ^a   Schlüter, Torsten ^a   Reimer, Nico ^a   Zimmermann, Uwe ^a   Katsari, Elpiniki ^b   Plettenburg, Oliver ^b   Löhn, Matthias ^b   Wollert, Hans Georg ^b   Rettig, Rainer ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

antihypertensive agents; blood pressure; Rho kinase; vascular resistance; vascular smooth muscle

Indexed keywords

ENDOTHELIN 1; MESSENGER RNA; RHO KINASE INHIBITOR; SAR 407899; UNCLASSIFIED DRUG; Y 27623;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DARK AGOUTI RAT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN TISSUE; ISOLATED ARTERY; MALE; MUSIC; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RENAL ARTERY; RESISTANCE BLOOD VESSEL; THYMUS; VASOCONSTRICTION; ZUCKER DIABETIC FATTY RAT;

EID: 84859893278     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328351d459     Document Type: Article

References (42)

1. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98:322-334.
2. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta 2010; 1802:1276-1284.
3. Schubert R, Lidington D, Bolz SS. The emerging role of Ca2 + sensitivity regulation in promoting myogenic vasoconstriction. Cardiovasc Res 2008; 77:8-18. (Pubitemid 351195169)
4. Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, Surks HK. Rock isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res 2009; 104:531-540.
5. Liao JK, Seto M, Noma K. Rho kinase (rock) inhibitors. J Cardiovasc Pharmacol 2007; 50:17-24. (Pubitemid 47220442)
6. Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, et al. Pharmacological characterization of sar407899, a novel rho-kinase inhibitor. Hypertension 2009; 54:676-683.
7. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38:1307-1310. (Pubitemid 34033407)
8. Bussemaker E, Herbrig K, Pistrosch F, Palm C, Passauer J. Role of rhokinase in the regulation of vascular tone in hypertensive renal transplant recipients. Atherosclerosis 2009; 207:567-572.
9. Daemen MJ, De Mey JG. Regional heterogeneity of arterial structural changes. Hypertension 1995; 25:464-473.
10. Hill CE, Phillips JK, Sandow SL. Heterogeneous control of blood flow amongst different vascular beds. Med Res Rev 2001; 21:1-60. (Pubitemid 32037521)
11. Weiss S, Frischknecht K, Greutert H, Payeli S, Steffel J, Luscher TF, et al. Different migration of vascular smooth muscle cells from human coronary artery bypass vessels. Role of rho/rock pathway. J Vasc Res 2007; 44:149-156.
12. Rettig R, Grisk O. The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies. Hypertension 2005; 46:463-468. (Pubitemid 41376819)
13. Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 2009; 296:R1001-R1018.
14. Guyton AC. Blood pressure control: special role of the kidneys and body fluids. Science 1991; 252:1813-1816. (Pubitemid 21917099)
15. Grisk O, Frauendorf T, Schluter T, Kloting I, Kuttler B, Krebs A, et al. Impaired coronary function in wistar Ottawa Karlsburg w rats: a new model of the metabolic syndrome. Pflugers Arch 2007; 454:1011-1021. (Pubitemid 47338464)
16. Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, Yorek MA. Progression of coronary and mesenteric vascular dysfunction in zucker obese and zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 2006; 291:H1780-H1787. (Pubitemid 44497684)
17. Lu X, Guo X, Karathanasis SK, Zimmerman KM, Onyia JE, Peterson RG, Kassab GS. Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in zucker diabetic fatty rats. Cardiovasc Diabetol 2010; 9:19.
18. Goode GK, Heagerty AM. In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy. Circulation 1995; 91:2898-2903.
19. Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens 2009; 27:1107-1114.
20. Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH, De Vriese AS. A neutralizing vegf antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the zucker diabetic fatty rat. Nephrol Dial Transplant 2006; 21:324-329. (Pubitemid 43159984)
21. Izuhara Y, Sada T, Yanagisawa H, Koike H, Ohtomo S, Dan T, et al. A novel sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008; 28:1767-1773.
22. Toblli J, Cao G, Rivas C, Munoz M, Giani J, Dominici F, Angerosa M. Cardiovascular protective effects of nebivolol in zucker diabetic fatty rats. J Hypertens 2010; 28:1007-1019.
23. Schluter T, Steinbach AC, Steffen A, Rettig R, Grisk O. Apocynininduced vasodilation involves rho kinase inhibition but not nadph oxidase inhibition. Cardiovasc Res 2008; 80:271-279.
24. Schluter T, Rohsius R, Wanka H, Schmid C, Siepelmeyer A, Rettig R, et al. Amiloride lowers arterial pressure in cyp1a1ren-2 transgenic rats without affecting renal vascular function. J Hypertens 2010; 28:2267-2277.
25. Schluter T, Zimmermann U, Protzel C, Miehe B, Klebingat KJ, Rettig R, Grisk O. Intrarenal artery superoxide is mainly nadph oxidase-derived and modulates endothelium-dependent dilation in elderly patients. Cardiovasc Res 2010; 85:814-824.
26. Mulvany MJ. Small artery remodelling in hypertension: causes, consequences and therapeutic implications. Med Biol Eng Comput 2008; 46:461-467.
27. Martinez-Lemus LA, Hill MA, Meininger GA. The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology (Bethesda) 2009; 24:45-57.
28. Folkow B. Hypertensive structural changes in systemic precapillary resistance vessels: how important are they for in vivo haemodynamics? J Hypertens 1995; 13:1546-1559. (Pubitemid 26015773)
29. Rizzoni D, Porteri E, Boari GE, De Ciuceis C, Sleiman I, Muiesan ML, et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003; 108:2230-2235. (Pubitemid 37363040)
30. Mathiassen ON, Buus NH, Sihm I, Thybo NK, Morn B, Schroeder AP, et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 2007; 25:1021-1026. (Pubitemid 46573121)
31. Rizzoni D, Rosei EA. Small artery remodeling in diabetes mellitus. Nutr Metab Cardiovasc Dis 2009; 19:587-592.
32. Mathiassen ON, Buus NH, Larsen ML, Mulvany MJ, Christensen KL. Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment. J Hypertens 2007; 25:1027-1034. (Pubitemid 46573122)
33. Ocaranza MP, Rivera P, Novoa U, Pinto M, Gonzalez L, Chiong M, et al. Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. J Hypertens 2011; 29:706-715.
34. Crowley CM, Lee CH, Gin SA, Keep AM, Cook RC, Van Breemen C. The mechanism of excitation-contraction coupling in phenylephrinestimulated human saphenous vein. Am J Physiol Heart Circ Physiol 2002; 283:H1271-H1281.
35. Noma K, Goto C, Nishioka K, Hara K, Kimura M, Umemura T, et al. Smoking, endothelial function, and rho-kinase in humans. Arterioscler Thromb Vasc Biol 2005; 25:2630-2635. (Pubitemid 43732289)
36. Hein TW, Rosa RH Jr, Yuan Z, Roberts E, Kuo L. Divergent roles of nitric oxide and rho kinase in vasomotor regulation of human retinal arterioles. Invest Ophthalmol Vis Sci 2010; 51:1583-1590.
37. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990; 70:921-961. (Pubitemid 20364819)
38. Gong R, Dworkin LD, Brenner BM, Maddox DA. The renal circulation and glomerular ultrafiltration. In: Brenner BM, editor. The kidney. Philadelphia: Saunders; 2008. pp. 91-129.
39. Thorin E, Webb DJ. Endothelium-derived endothelin-1. Pflugers Arch 2010; 459:951-958.
40. Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993; 73:375-411.
41. Naik JS, Xiang L, Hester RL. Enhanced role for rhoa-associated kinase in adrenergic-mediated vasoconstriction in gracilis arteries from obese zucker rats. Am J Physiol Regul Integr Comp Physiol 2006; 290:R154-R161.
42. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.